Researchers identify chemical compound that inhibits Ebola virus replication

March 28, 2018

ATLANTA--An organic chemical compound shows effective antiviral activity against Ebola virus and several other viruses, according to a study led by Georgia State University.

The researchers found benzoquinoline inhibited the ability of Ebola virus to multiply and reproduce in cell culture. The findings are published in the journal Antiviral Research.

Ebola virus, a member of the filovirus family, is an enveloped, single-stranded RNA virus that causes severe disease in humans. The largest outbreak on record for the filovirus family was caused by Ebola virus in West Africa between 2013 and 2016, resulting in more than 28,000 infections and more than 11,000 deaths.

Only experimental treatments were available, and survivors, including health care workers, are at risk for persistent infections from the virus remaining in sites that can tolerate foreign substances without eliciting an inflammatory immune response, such as the eye and testes. There are no approved drugs to treat Ebola virus or other filovirus infections, so there is a critical need for new therapeutic approaches. A potential antiviral target is the viral machinery and activities involved in carrying out RNA synthesis for Ebola virus.

"This work provides a foundation for the development of novel antiviral agents to combat Ebola virus," said Dr. Christopher Basler, director of the Center for Microbial Pathogenesis and professor in the Institute for Biomedical Sciences at Georgia State and a Georgia Research Alliance Eminent Scholar in Microbial Pathogenesis.

In this study, the researchers screened a library of 200,000 small molecule compounds to identify potential inhibitors of Ebola virus RNA synthesis. They identified 56 hits that inhibited Ebola virus activity by more than 70 percent, while showing less than a 20 percent chance of being toxic to cells. They discovered three chemical structures with potent antiviral activity against Ebola virus in cell culture.

Human lung epithelial cells and human embryonic kidney cells were exposed to several viruses, Ebola virus, Marburg virus, vesicular stomatitis virus and Zika virus, and the antiviral effects of the three chemical structures were observed.

One of these chemical structures, benzoquinoline, showed antiviral activity against Ebola virus and was also active against another deadly filovirus, Marburg virus. Benzoquinoline was also effective against vesicular stomatitis virus from the rhabdovirus family, which can infect insects, cattle, horses and pigs, and Zika virus, which is spread to humans by mosquitoes.

"This study is part of a larger effort to find new therapies to treat highly dangerous Ebola virus infections," said lead author Dr. Priya Luthra of Georgia State.
-end-
Co-authors of the study include Sudip Khadka, Megan R. Edwards and Sampriti De of Georgia State; Jue Liang, Shuguang Wei, Bruce Posner and Joseph M. Ready of the University of Texas Southwestern Medical Center; and Colette A. Pietzsch and Alexander Bukreyev of the University of Texas Medical Branch at Galveston.

The study is funded by the National Institutes of Health.

To read the study, visit https://www.sciencedirect.com/science/article/pii/S016635421730640X.

Georgia State University

Related Ebola Virus Articles from Brightsurf:

Targeting the shell of the Ebola virus
As the world grapples with COVID-19, the Ebola virus is again raging.

New universal Ebola vaccine may fight all four virus species that infect humans
Infectious disease scientists report early development of a potential universal vaccine for Ebola viruses that preclinical tests show might neutralize all four species of these deadly viruses infecting people in recent outbreaks, mainly in Africa.

Researchers show how Ebola virus hijacks host lipids
Robert Stahelin studies some of the world's deadliest viruses. Filoviruses, including Ebola virus and Marburg virus, cause viral hemorrhagic fever with high fatality rates.

Recognise and control new variants of the deadly Ebola virus more quickly
Joint press release by the DZIF and Charité. The situation is extraordinary: there have only ever been four declarations of public health emergencies of international concern in the past and now there are two at the same time.

Investigational drugs reduce risk of death from Ebola virus disease
The investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease (EVD) compared to the investigational treatment ZMapp, according to published results from a clinical trial conducted in the Democratic Republic of the Congo (DRC).

Researchers learn how Ebola virus disables the body's immune defenses
A new study by researchers from The University of Texas Medical Branch at Galveston uncovered new information on why the Ebola virus can exert such catastrophic effects on the infected person.

Mutant live attenuated Ebola virus immunizes non-human primates
Inoculation with an Ebola virus that has mutations in a protein called VP35 does not cause disease and elicits protection in monkeys, researchers show Sept.

Groundbreaking study could lead to fast, simple test for Ebola virus
In a breakthrough that could lead to a simple and inexpensive test for Ebola virus disease, researchers have generated two antibodies to the deadly virus.

RIT professor develops microfluidic device to better detect Ebola virus
A faculty-researcher at Rochester Institute of technology has developed a prototype micro device with bio-sensors that can detect the deadly Ebola virus.

NEJM applying universal standards of care to Ebola virus disease
LSTM's Senior Clinical Lecturer, Dr. Shevin Jacob, is corresponding author on a perspective piece published in the New England Journal of Medicine calling for universal standards of care to be applied in relation to ebola virus disease.

Read More: Ebola Virus News and Ebola Virus Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.